Background. Autologous whole blood and platelet-rich plasma (PRP) have been both suggested to treat chronic tennis elbow. The aim of the present study was to compare the effects of PRP versus autologous whole blood local injection in chronic tennis elbow. Methods. Forty patients with tennis elbow were randomly divided into 2 groups. Group 1 was treated with a single injection of 2？mL of autologous PRP and group 2 with 2？mL of autologous blood. Tennis elbow strap, stretching, and strengthening exercises were administered for both groups during a 2-month followup. Pain and functional improvements were assessed using visual analog scale (VAS), modified Mayo Clinic performance index for the elbow, and pressure pain threshold (PPT) at 0, 4, and 8 weeks. Results. All pain and functional variables including VAS, PPT, and Mayo scores improved significantly in both groups 4 weeks after injection. No statistically significant difference was noted between groups regarding pain scores in 4-week follow-up examination ( ). At 8-week reevaluations, VAS and Mayo scores improved only in PRP group ( ). Conclusion. PRP and autologous whole blood injections are both effective to treat chronic lateral epicondylitis. PRP might be slightly superior in 8-week followup. However, further studies are suggested to get definite conclusion. 1. Background Lateral epicondylitis known as tennis elbow is a repetitive strain injury caused by repetitive overuse of the extensor muscles of the wrist. It is the most frequent type of myotendinosis occurring more specifically at the common extensor tendon that originates from the lateral epicondyle [1, 2]. The frequency of lateral epicondylitis is reported between 1 to 3% among normal nonathlete population [3]. Epicondylitis was initially believed to be an inflammatory process but in 1979, it was described as the disorganization of normal collagen architecture by invading fibroblasts in association with an immature vascular reparative response, which termed “angiofibroblastic hyperplasia” [1, 2]. It causes pain and functional impairment in daily activities [2, 3]. The treatment of this condition includes conservative therapy and surgical interventions [3, 4]. The effectiveness of oral nonsteroidal anti-inflammatory agents, topical and injectable medications including corticosteroids and botulinum toxins, splinting, physical therapy, and iontophoresis has been evaluated in many studies [4]. However, these traditional therapies do not alter the tendon’s inherent poor healing properties secondary to poor vascularization [5, 6]. Given the inherent
References
[1]
M. A. Childress and A. Beutler, “Management of chronic tendon injuries,” American Family Physician, vol. 87, pp. 486–490, 2013.
[2]
A. O. Chourasia, K. A. Buhr, D. P. Rabago, et al., “Relationships between biomechanics, tendon pathology, and function in individuals with lateral epicondylosis,” Journal of Orthopaedic & Sports Physical Therapy, vol. 43, pp. 368–378, 2013.
[3]
A. Mishra and T. Pavelko, “Treatment of chronic elbow tendinosis with buffered platelet-rich plasma,” American Journal of Sports Medicine, vol. 34, no. 11, pp. 1774–1778, 2006.
[4]
J. C. Peerbooms, J. Sluimer, D. J. Bruijn, and T. Gosens, “Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up,” American Journal of Sports Medicine, vol. 38, no. 2, pp. 255–262, 2010.
[5]
M. Kazemi, K. Azma, B. Tavana, F. Rezaiee Moghaddam, and A. Panahi, “Autologous blood versus corticosteroid local injection in the short-term treatment of lateral elbow tendinopathy: a randomized clinical trial of efficacy,” American Journal of Physical Medicine and Rehabilitation, vol. 89, no. 8, pp. 660–667, 2010.
[6]
T. Molloy, Y. Wang, and G. A. C. Murrell, “The roles of growth factors in tendon and ligament healing,” Sports Medicine, vol. 33, no. 5, pp. 381–394, 2003.
[7]
D. Crane and P. Everts, “Platelet rich plasma (PRP) matrix grafts,” Practical Pain Management, vol. 8, pp. 11–26, 2008.
[8]
K. Tate and D. Crane, “Platelet rich plasma grafts in musculoskeletal medicine,” The Journal of Prolotherapy, vol. 2, pp. 371–376, 2010.
[9]
S. Sampson, M. Gerhardt, and B. Mandelbaum, “Platelet rich plasma injection grafts for musculoskeletal injuries: a review,” Ethics in Science and Environmental Politics, pp. 1–10, 2008.
[10]
S. G. Edwards and J. H. Calandruccio, “Autologous blood injections for refractory lateral epicondylitis,” Journal of Hand Surgery, vol. 28, no. 2, pp. 272–278, 2003.
[11]
D. A. Connell, K. E. Ali, M. Ahmad, S. Lambert, S. Corbett, and M. Curtis, “Ultrasound-guided autologous blood injection for tennis elbow,” Skeletal Radiology, vol. 35, no. 6, pp. 371–377, 2006.
[12]
C. Thanasas, G. Papadimitriou, C. Charalambidis, I. Paraskevopoulos, and A. Papanikolaou, “Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial,” American Journal of Sports Medicine, vol. 39, no. 10, pp. 2130–2134, 2011.
[13]
A. M. Boonstra, H. R. Schiphorst Preuper, M. F. Reneman, J. B. Posthumus, and R. E. Stewart, “Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain,” International Journal of Rehabilitation Research, vol. 31, no. 2, pp. 165–169, 2008.
[14]
D. D. Price, F. M. Bush, S. Long, and S. W. Harkins, “A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales,” Pain, vol. 56, no. 2, pp. 217–226, 1994.
[15]
D. C. Turchin, D. E. Beaton, and R. R. Richards, “Validity of observer-based aggregate scoring systems as descriptors of elbow pain, function, and disability,” Journal of Bone and Joint Surgery. American, vol. 80, no. 2, pp. 154–162, 1998.
[16]
B. F. Morrey and K. N. An, “Functional evaluation of the elbow,” in The Elbow and Its Disorders, B. F. Morrey, Ed., p. 82, WB Saunders, Philadelphia, Pa, USA, 3rd edition, 2000.
[17]
Y. A. De Boer, J. M. W. Hazes, P. C. A. Winia, R. Brand, and P. M. Rozing, “Comparative responsiveness of four elbow scoring instruments in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 28, no. 12, pp. 2616–2623, 2001.
[18]
L. Creaney, A. Wallace, M. Curtis, and D. Connell, “Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: a prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections,” British Journal of Sports Medicine, vol. 45, no. 12, pp. 966–971, 2011.
[19]
D. Rabago, T. M. Best, A. E. Zgierska, E. Zeisig, M. Ryan, and D. Crane, “A systematic review of four injection therapies for lateral epicondylosis: prolotherapy, polidocanol, whole blood and platelet-rich plasma,” British Journal of Sports Medicine, vol. 43, no. 7, pp. 471–481, 2009.
[20]
J. F. Kaux and J. M. Crielaard, “Platelet-rich plasma application in the management of chronic tendinopathies,” Acta Orthopaedica Belgica, vol. 79, pp. 10–15, 2013.
[21]
R. S. Dhillon, E. M. Schwarz, and M. D. Maloney, “Platelet-rich plasma therapy—future or trend?” Arthritis Research & Therapy, vol. 14, p. 219, 2012.
[22]
S. A. Raeissadat, S. M. Rayegani, M. Babaee, and E. Ghorbani, “The effect of platelet-rich plasma on pain, function, and quality of life of patients with knee osteoarthritis,” Pain Research and Treatment, vol. 2013, Article ID 165967, 7 pages, 2013.
[23]
E. Kon and G. Filardo, “PRP or not PRP? That is the question,” Knee Surgery, Sports Traumatology, Arthroscopy, vol. 19, no. 6, pp. 870–871, 2011.
[24]
R. R. Monto, “Platelet rich plasma treatment for chronic Achilles tendinosis,” Foot & Ankle International, vol. 33, pp. 379–385, 2012.
[25]
T. Gosens, B. L. Den Oudsten, E. Fievez, P. van 't Spijker, and A. Fievez, “Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy: a prospective cohort study and the influence of previous treatments,” International Orthopaedics, vol. 36, no. 9, pp. 1941–1946, 2012.
